Medopharm is a finished-dose manufacturer based in India. It appears in 94 regulatory filings across 5 regulators, without an active US DMF or CEP on file. Its filings concentrate with EFDA (ET), NAFDAC (NG) and ZAMRA (ZM). Its GMP standing is certified by EMA, NAFDAC (NG) and FDA (GH), among 4 authorities. Customs aggregates show $29.5M of exports covering 1,497 molecules to 60 destinations in 2025.
| Site | FDA FEI |
|---|---|
| CHENGALPET DISTRICT, India | Not on file |
| Karnataka State, Nigeria | Not on file |
| Guduvanchery, Nigeria | Not on file |
| Regulator | Filings | GMP certificates |
|---|---|---|
| EFDA (ET) | 54 | None |
| NAFDAC (NG) | 19 | 2 |
| ZAMRA (ZM) | 12 | None |
| TMDA (TZ) | 8 | None |
| MCAZ (ZW) | 1 | None |
| EMA | None | 2 |
| FDA (GH) | None | 1 |
| MHRA (UK) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $7.5M | 38 |
| 2025 | Not reported | $29.5M | 60 |
| 2024 | Not reported | $33.7M | 64 |
| 2023 | Not reported | $35.8M | 64 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Medopharm comes back tiered against every other supplier able to file there.
Start for free